ArticleOncotarget2014
miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 74 citations in OpenAlex.
- Readers of RNA Modification in Cancer and Their Anticancer Inhibitors.Biomolecules · 2024Review
- MicroRNA expression alteration in chronic thromboembolic pulmonary hypertension: A systematic review.Pulmonary circulation · 2024Article
- The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets.Frontiers in cell and developmental biology · 2022Review
- Geiparvarin Inhibits OS Metastasis through Upregulation of ANGPTL4 Expression by Inhibiting miRNA-3912-3p Expression.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Long non-coding RNA NEAT1 transported by extracellular vesicles contributes to breast cancer development by sponging microRNA-141-3p and regulating KLF12.Cell & bioscience · 2021Article
- Downregulation of Circ_0071589 Suppresses Cisplatin Resistance in Colorectal Cancer by Regulating the MiR-526b-3p/KLF12 Axis.Cancer management and research · 2021Article
- Overexpression of miR-382 Sensitizes Hepatocellular Carcinoma Cells to γδ T Cells by Inhibiting the Expression of c-FLIP.Molecular therapy oncolytics · 2020Article
- Circular RNA hsa_circ_0002052 promotes osteosarcoma via modulating miR-382/STX6 axis.Human cell · 2020Article
- Hsa_circ_0000285 functions as a competitive endogenous RNA to promote osteosarcoma progression by sponging hsa-miRNA-599.Gene therapy · 2020Article
- Article
- Circular RNA hsa_circ_0003496 Contributes to Tumorigenesis and Chemoresistance in Osteosarcoma Through Targeting (microRNA) miR-370/Krüppel-Like Factor 12 Axis.Cancer management and research · 2020Article
- Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression.Nature communications · 2019Article
- MiR-382 functions as tumor suppressor and chemosensitizer in colorectal cancer.Bioscience reports · 2019Article
- KLF12 Regulates Mouse NK Cell Proliferation.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- miR-363 acts as a tumor suppressor in osteosarcoma cells by inhibiting PDZD2.Oncology reports · 2019Article
- MicroRNA-638 expression change in osteosarcoma patients via PLD1 and VEGF expression.Experimental and therapeutic medicine · 2019Article
- Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies.Journal of cellular and molecular medicine · 2019Review
- MicroRNA-382 inhibits cancer cell growth and metastasis in NSCLC via targeting LMO3.Experimental and therapeutic medicine · 2019Article
- SNHG1 contributes to proliferation and invasion by regulating miR-382 in breast cancer.Cancer management and research · 2019Article
- Clinical significance and prognostic role of hypoxia-induced microRNA 382 in gastric adenocarcinoma.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of miRNAs is involved in osteosarcoma (OS). Here, we demonstrate that miR-382 is decreased in specimens of OS patients with a poor chemoresponse compared to those with a good chemoresponse. In addition, our clinical data show that decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting KLF12 and HIPK3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. Taken together, these findings suggest that miR-382 is a tumor suppressor miRNA and induction of miR-382 is a potential strategy to inhibit OS progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.